Conclusion: Large HCC by itself is not a contraindication for surgery and curative resection remains the treatment of choice in patients with good performance status and preserved liver function. TACE followed by PVE is the preferred method for FLR augmentation to facilitate curative resection in these cases. Sorafenib is the drug of choice in case of disease progression or metastasis after curative resection. Upfront resectable local recurrence should be operated to negative margins in appropriately selected cases. Regorafenib or cabozantinib are second line agents for HCC after sorafenib resistance or intolerance.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.